Hepatocyte growth factor and Met in drug discovery

Journal of Biochemistry

Volumn 157, Issue 5, 2015, Pages 271-284

  Sakai, Katsuya ^a   Aoki, Shunsuke ^b   Matsumoto, Kunio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

drug resistance; growth factor; molecular targeted drugs; receptor tyrosine kinase; regenerative medicine

Indexed keywords

PEPTIDE; PROTEIN INHIBITOR; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; SCATTER FACTOR INHIBITOR; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; MET PROTEIN, HUMAN; PROTEIN BINDING;

ACUTE KIDNEY FAILURE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CRITICAL LIMB ISCHEMIA; DRUG TARGETING; GENE THERAPY; HEPATITIS; HOMEOSTASIS; HUMAN; LEG ULCER; LIVER CELL; LIVER REGENERATION; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE;

ANIMALS; DRUG DISCOVERY; HEPATOCYTE GROWTH FACTOR; HOMEOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84941113254     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvv027     Document Type: Article

References (88)

1. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., Tashiro, K., and Shimizu, S. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443
2. Miyazawa, K., Tsubouchi, H., Naka, D., Takahashi, K., Okigaki, M., Arakaki, N., Nakayama, H., Hirono, S., Sakiyama, O., Takahashi, K., Gohda, E., Daikuhara, Y., and Kitamura, N. (1989) Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163, 967-973
3. Weidner, K.M., Behrens, J., Vanderkerckhove, J., and Birchmeier, W. (1990) Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111, 2097-2108
4. Bottaro, D.P., Rubin, J.S., Faletto, D.L., Chan, A.-M.I., Kmiecik, T.E., Vande Woude, G.F., and Aaronson, S.A. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804
5. Naldini, L., Vigna, E., Narcimham, R.P., Gaudino, G., Zarnegar, R., Michalopoulos, G.K., and Comoglio, P.M. (1991) Hepatocyte growth factor stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6, 501-504
6. Montesano, R., Matsumoto, K., Nakamura, T., and Orci, L. (1991) Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67, 901-908
7. Nakamura, T., Sakai, K., Nakamura, T., and Matsumoto, K. (2011) Hepatocyte growth factor twenty years on: much more than a growth factor. J. Gastroenterol. Hepatol. 26, 188-202
8. Martin, T.A. and Jiang, W.G. (2010) Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anticancer Agents Med. Chem. 10, 2-6
9. Cecchi, F., Rabe, D.C., and Bottaro, D.P. (2012) Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16, 553-572
10. Gherardi, E., Birchmeier, W., Birchmeier, C., and Vande Woude, G.F. (2012) Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89-103
11. Kataoka, H., Miyata, S., Uchinokura, S., and Itoh, H. (2003) Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev. 22, 223-236
12. Gherardi, E., Sandin, S., Petoukhov, M.V., Finch, J., Youles, M.E., Ofverstedt, L.G., Miguel, R.N., Blundell, T.L., Vande Woude, G.F., Skoglund, U., and Svergun, D.I. (2006) Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl Acad. Sci. USA 103, 4046-4051
13. Basilico, C., Arnesano, A., Galluzzo, M., Comoglio, P.M., and Michieli, P. (2008) A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem. 283, 21267-21277
14. Matsumoto, K., Kataoka, H., Date, K., and Nakamura, T. (1998) Cooperative interaction between a-chain and b-chain of HGF on c-Met receptor confers ligandinduced receptor tyrosine phosphorylation and multiple biological responses. J. Biol. Chem. 273, 22913-22920
15. Stamos, J., Lazarus, R.A., Yao, X., Kirchhofer, D., and Wiesmann, C. (2004) Crystal structure of the HGF bchain in complex with the Sema domain of the Met receptor. EMBO J. 23, 2325-2335
16. Merchant, M., Ma, X., Maun, H.R., Zheng, Z., Peng, J., Romero, M., Huang, A., Yang, N.Y., Nishimura, M., Greve, J., Santell, L., Zhang, Y.W., Su, Y., Kaufman, D.W., Billeci, K.L., Mai, E., Moffat, B., Lim, A., Duenas, E.T., Phillips, H.S., Xiang, H., Young, J.C., Vande Woude, G.F., Dennis, M.S., Reilly, D.E., Schwall, R.H., Starovasnik, M.A., Lazarus, R.A., and Yansura, D.G. (2013) Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc. Natl Acad. Sci. USA 110, E2987-E2996
17. Schiering, N., Knapp, S., Marconi, M., Flocco, M.M., Cui, J., Perego, R., Rusconi, L., and Cristiani, C. (2003) Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl Acad. Sci. USA 100, 12654-12659
18. Wang, W., Marimuthu, A., Tsai, J., Kumar, A., Krupka, H.I., Zhang, C., Powell, B., Suzuki, Y., Nguyen, H., Tabrizizad, M., Luu, C., and West, B.L. (2006) Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl Acad. Sci. USA 103, 3563-3588
19. Sachs, M., Brohmann, H., Zechner, D., Mü ller, T., Hü lsken, J., Walther, I., Schaeper, U., Birchmeier, C., and Birchmeier, W. (2000) Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375-1384
20. Peschard, P., Fournier, T.M., Lamorte, L., Naujokas, M.A., Band, H., Langdon, W.Y., and Park, M. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004
21. Hashigasako, A., Machide, M., Nakamura, T., Matsumoto, K., and Nakamura, T. (2004) Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J. Biol. Chem. 279, 26445-26452
22. Nakayama, M., Sakai, K., Yamashita, A., Nakamura, T., Suzuki, Y., and Matsumoto, K. (2013) Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes. Cytokine 62, 446-452
23. Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., and Kitamura, N. (1995) Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702-705
24. Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., and Birchmeier, C. (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699-702
25. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier, C. (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771
26. Huh, C.G., Factor, V.M., Sanchez, A., Uchida, K., Conner, E.A., and Thorgeirsson, S.S. (2004) Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci. USA 101, 4477-4482
27. Factor, V.M., Seo, D., Ishikawa, T., Kaposi-Novak, P., Marquardt, J.U., Andersen, J.B., Conner, E.A., and Thorgeirsson, S.S. (2010) Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. PLoS One 5, e12739
28. Borowiak, M., Garratt, A.N., Wustefeld, T., Strehle, M., Trautwein, C., and Birchmeier, C. (2004) Met provides essential signals for liver regeneration. Proc. Natl Acad. Sci. USA 101, 10608-10613
29. Marquardt, J.U., Seo, D., Gó mez-Quiroz, L.E., Uchida, K., Gillen, M.C., Kitade, M., Kaposi-Novak, P., Conner, E.A., Factor, V.M., and Thorgeirsson, S.S. (2012) Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways. Biochim. Biophys. Acta 1822, 942-951
30. Giebeler, A., Boekschoten, M.V., Klein, C., Borowiak, M., Birchmeier, C., Gassler, N., Wasmuth, H.E., Mü ller, M., Trautwein, C., and Streetz, K.L. (2009) c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology 137, 297-308
31. Del Castillo, G., Factor, V.M., Ferná ndez, M., Alvarez-Barrientos, A., Fabregat, I., Thorgeirsson, S.S., and Sá nchez, A. (2008) Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro. Am. J. Pathol. 172, 1238-1247
32. Ishikawa, T., Factor, V.M., Marquardt, J.U., Raggi, C., Seo, D., Kitade, M., Conner, E.A., and Thorgeirsson, S.S. (2012) Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology 55, 1215-1226
33. Zhou, D., Tan, R.J., Lin, L., Zhou, L., and Liu, Y. (2013) Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int. 84, 509-520
34. Dai, C., Saleem, M.A., Holzman, L.B., Mathieson, P., and Liu, Y. (2010) Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int. 77, 962-973
35. Ma, H., Saenko, M., Opuko, A., Togawa, A., Soda, K., Marlier, A., Moeckel, G.W., Cantley, L.G., and Ishibe, S. (2009) Deletion of the Met receptor in the collecting duct decreases renal repair following ureteral obstruction. Kidney Int. 76, 868-876
36. Ishibe, S., Karihaloo, A., Ma, H., Zhang, J., Marlier, A., Mitobe, M., Togawa, A., Schmitt, R., Czyczk, J., Kashgarian, M., Geller, D.S., Thorgeirsson, S.S., and Cantley, L.G. (2009) Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 136, 337-345
37. Chmielowiec, J., Borowiak, M., Morkel, M., Stradal, T., Munz, B., Werner, S., Wehland, J., Birchmeier, C., and Birchmeier, W. (2007) c-Met is essential for wound healing in the skin. J. Cell Biol. 177, 151-162
38. Dai, C., Huh, C.G., Thorgeirsson, S.S., and Liu, Y. (2005) b-Cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am. J. Pathol. 167, 429-436
39. Roccisana, J., Reddy, V., Vasavada, R.C., Gonzalez-Pertusa, J.A., Magnuson, M.A., and Garcia-Ocanã, A. (2005) Targeted inactivation of hepatocyte growth factor receptor c-met in b-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of b-cell mass. Diabetes 54, 2090-2102
40. Mellado-Gil, J., Rosa, T.C., Demirci, C., Gonzalez-Pertusa, J.A., Velazquez-Garcia, S., Ernst, S., Valle, S., Vasavada, R.C., Stewart, A.F., Alonso, L.C., and Garcia-Ocanã, A. (2011) Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic b-cell death and accelerates the onset of diabetes. Diabetes 60, 525-536
41. Judson, M.C., Eagleson, K.L., Wang, L., and Levitt, P. (2010) Evidence of cell-nonautonomous changes in dendrite and dendritic spine morphology in the met-signaling-deficient mouse forebrain. J. Comp. Neurol. 518, 4463-4478
42. Qiu, S., Anderson, C.T., Levitt, P., and Shepherd, G.M. (2011) Circuit-specific intracortical hyperconnectivity in mice with deletion of the autism-associated Met receptor tyrosine kinase. J. Neurosci. 31, 5855-5864
43. Arechederra, M., Carmona, R., Gonzá lez-Nuñ ez, M., Gutiérrez-Uzquiza, A., Bragado, P., Cruz-Gonzá lez, I., Cano, E., Guerrero, C., Sá nchez, A., Ló pez-Novoa, J.M., Schneider, M.D., Maina, F., Muñ oz-Chá puli, R., and Porras, A. (2013) Met signaling in cardiomyocytes is required for normal cardiac function in adult mice. Biochim. Biophys. Acta 1832, 2204-2215
44. Baek, J.H., Birchmeier, C., Zenke, M., and Hieronymus, T. (2012) The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J. Immunol. 189, 1699-1707
45. Judson, M.C., Eagleson, K.L., and Levitt, P. (2011) A new synaptic player leading to autism risk: Met receptor tyrosine kinase. J. Neurodev. Disord. 3, 282-292
46. Campbell, D.B., Sutcliffe, J.S., Ebert, P.J., Militerni, R., Bravaccio, C., Trillo, S., Elia, M., Schneider, C., Melmed, R., Sacco, R., Persico, A.M., and Levitt, P. (2006) A genetic variant that disrupts MET transcription is associated with autism. Proc. Natl Acad. Sci. USA 103, 16834-16839
47. Buchstein, N., Hoffmann, D., Smola, H., Lang, S., Paulsson, M., Niemann, C., Krieg, T., and Eming, S.A. (2009) Alternative proteolytic processing of hepatocyte growth factor during wound repair. Am. J. Pathol. 174, 2116-2128
48. Bevan, D., Gherardi, E., Fan, T.P., Edwards, D., and Warn, R. (2004) Diverse and potent activities of HGF/ SF in skin wound repair. J. Pathol. 203, 831-838
49. Yoshida, S., Matsumoto, K., Tomioka, D., Bessho, K., Itami, S., Yoshikawa, K., and Nakamura, T. (2004) Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model. Growth Factors 22, 111-119
50. Nayeri, F., Strö mberg, T., Larsson, M., Brudin, L., Sö derströ m, C., and Forsberg, P. (2002) Hepatocyte growth factor may accelerate healing in chronic leg ulcers: A pilot study. J. Dermatol. Treat. 13, 81-86
51. Rosen, E.M., Jaken, S., Carley, W., Luckett, P.M., Setter, E., Bhargava, M., and Goldberg, I.D. (1991) Regulation of motility in bovine brain endothelial cells. J. Cell Physiol. 146, 325-335
52. Morimoto, A., Okamura, K., Hamanaka, R., Sato, Y., Shima, N., Higashio, K., and Kuwano, M. (1991) Hepatocyte growth factor modulates migration and proliferation of human microvascular endothelial cells in culture. Biochem. Biophys. Res. Commun. 179, 1042-1049
53. Bussolino, F., di Renzo, M.F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., and Comoglio, P.M. (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629-641
54. Van Belle, E., Witzenbichler, B., Chen, D., Silver, M., Chang, L., Schwall, R., and Isner, J.M. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97, 381-390
55. Taniyama, Y., Morishita, R., Aoki, M., Nakagami, H., Yamamoto, K., Yamazaki, K., Matsumoto, K., Nakamura, T., Kaneda, Y., and Ogihara, T. (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 8, 181-189
56. Morishita, R., Aoki, M., Hashiya, N., Makino, H., Yamasaki, K., Azuma, J., Sawa, Y., Matsuda, H., Kaneda, Y., and Ogihara, T. (2004) Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44, 203-209
57. Shigematsu, H., Yasuda, K., Iwai, T., Sasajima, T., Ishimaru, S., Ohashi, Y., Yamaguchi, T., Ogihara, T., and Morishita, R. (2010) Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 17, 1152-1161
58. Shigematsu, H., Yasuda, K., Sasajima, T., Takano, T., Miyata, T., Ohta, T., Tanemoto, K., Obitsu, Y., Iwai, T., Ozaki, S., Ogihara, T., and Morishita, R. (2011) Transfection of human HGF plasmid DNA improves limb salvage in Buerger's disease patients with critical limb ischemia. Int. Angiol. 30, 140-149
59. Kosai, K., Matsumoto, K., Nagata, S., Tsujimoto, Y., and Nakamura, T. (1998) Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem. Biophys. Res. Commun. 244, 683-690
60. Ido, A., Moriuchi, A., Numata, M., Murayama, T., Teramukai, S., Marusawa, H., Yamaji, N., Setoyama, H., Kim, I.D., Chiba, T., Higuchi, S., Yokode, M., Fukushima, M., Shimizu, A., and Tsubouchi, H. (2011) Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety. J. Transl. Med. 9, 55
61. Funakoshi, F. and Nakamura, T. (2011) Hepatocyte growth factor (HGF): neurotrophic functions and therapeutic implications for neuronal injury/diseases. Curr. Signal Transduct. Ther. 6, 156-167
62. Sun, W., Funakoshi, H., and Nakamura, T. (2002) Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J. Neurosci. 22, 6537-6548
63. Ishigaki, A., Aoki, M., Nagai, M., Warita, H., Kato, S., Kato, M., Nakamura, T., Funakoshi, H., and Itoyama, Y. (2007) Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J. Neuropathol. Exp. Neurol. 66, 1037-1044
64. Kitamura, K., Fujiyoshi, K., Yamane, J., Toyota, F., Hikishima, K., Nomura, T., Funakoshi, H., Nakamura, T., Aoki, M., Toyama, Y., Okano, H., and Nakamura, M. (2011) Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury. PLoS One 6, e27706
65. Matsumoto, K., Horikoshi, M., Rikimaru, K., and Enomoto, S. (1989) A study of an in vitro model for invasion of oral squamous cell carcinoma. J. Oral Pathol. Med. 18, 498-501
66. Matsumoto, K. and Nakamura, T. (2006) Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 119, 477-483
67. Grotegut, S., von Schweinitz, D., Christofori, G., and Lehembre, F. (2006) Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J. 25, 3534-3545
68. Canãdas, I., Rojo, F., Taus, A., Arp, O., Arum?-Ur?á, M., Pijuan, L., Menéndez, S., Zazo, S., Dó mine, M., Salido, S., Mojal, A., Garc?á de Herreros, A., Rovira, A., Albanell, J., and Arriola, E. (2014) Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin. Cancer Res. 20, 938-950
69. Christensen, J.G., Burrows, J., and Salgia, R. (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225, 1-26
70. Comoglio, P.M., Giordano, S., and Trusolino, L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516
71. Hanahan, D. and Weinberg, R. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
72. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. New Engl. J. Med. 350, 2129-2139
73. Paez, J.G., Jä nne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500
74. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., and Nukiwa, T. North-East Japan Study Group. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl. J. Med. 362, 2380-2388
75. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., and Fukuoka, M. West Japan Oncology Group. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121-128
76. Morita, S., Okamoto, I., Kobayashi, K., Yamazaki, K., Asahina, H., Inoue, A., Hagiwara, K., Sunaga, N., Yanagitani, N., Hida, T., Yoshida, K., Hirashima, T., Yasumoto, K., Sugio, K., Mitsudomi, T., Fukuoka, M., and Nukiwa, T. (2009) Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin. Cancer Res. 15, 4493-4498
77. Kobayashi, S., Boggon, T.J., Dayaram, T., Jä nne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Eck, M.J., Tenen, D.C., and Halmos, B. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 352, 786-792
78. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A.J., Rogers, A.M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B.E., Cantley, L.C., and Jä nne, P.A. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043
79. Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., Uehara, H., Mitsudomi, T., Yatabe, Y., Nakamura, T., and Sone, S. (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with EGF Receptor activating mutations. Cancer Res. 68, 6479-6487
80. Turke, A.B., Zejnullahu, K., Wu, Y.L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N.I., Murphy, C., Akhavanfard, S., Yeap, B.Y., Xiao, Y., Capelletti, M., Iafrate, A.J., Lee, C., Christensen, J.G., Engelman, J.A., and Jä nne, P.A. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88
81. Yano, S., Takeuchi, S., Nakagawa, T., and Yamada, T. (2012) Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci. 103, 1189-1194
82. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., Cooper, Z.A., Chapman, P.B., Solit, D.B., Ribas, A., Lo, R.S., Flaherty, K.T., Ogino, S., Wargo, J.A., and Golub, T.R. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504
83. Tamase, A., Muraguchia, T., Naka, K., Tanaka, S., Kinoshita, M., Hoshii, T., Ohmura, M., Shugo, H., Ooshio, T., Nakada, M., Sawamoto, K., Onodera, M., Matsumoto, K., Oshima, M., Asano, M., Saya, H., Okano, H., Suda, T., Hamada, J., and Hirao, A. (2009) Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc. Natl Acad. Sci. USA 106, 17163-17168
84. De Bacco, F., Casanova, E., Medico, E., Pellegatta, S., Orzan, F., Albano, R., Luraghi, P., Reato, G., D'Ambrosio, A., Porrati, P., Patanè , M., Maderna, E., Pollo, B., Comoglio, P.M., Finocchiaro, G., and Boccaccio, C. (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 72, 4537-4550
85. Vermeulen, L., De Sousa, E., Melo, F., van der Heijden, M., Cameron, K., de Jong, J.H., Borovski, T., Tuynman, J.B., Todaro, M., Merz, C., Rodermond, H., Sprick, M.R., Kemper, K., Richel, D.J., Stassi, G., and Medema, J.P. (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476
86. Cui, J.J., Tran-Dubé , M., Shen, H., Nambu, M., Kung, P.P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., McTigue, M., Grodsky, N., Ryan, K., Padrique, E., Alton, G., Timofeevski, S., Yamazaki, S., Li, Q., Zou, H., Christensen, J., Mroczkowski, B., Bender, S., Kania, R.S., and Edwards, M.P. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342-6363
87. Ito, K., Passioura, T., and Suga, H. (2013) Technologies for the synthesis of mRNA-encoding libraries and discovery of bioactive natural product-inspired nontraditional macrocyclic peptides. Molecules 18, 3502-528
88. Ito, K., Sakai, K., Suzuki, Y., Ozawa, N., Hatta, T., Natsume, T., Matsumoto, K., and Suga, H. (2015) Artificial human Met agonists based on macrocycle scaffolds. Nat. Commun. 6, 6373